To investigate the possibility that gain-of-use of human TfR1 may not require extensive alteration of the TCRV and AMAV GPs, we sought to identify differences between human TfR1 and host animal TfR1 orthologs that determine the ability of these molecules to support infection by TCRV and AMAV pseudoviruses. This evidence concerns the gene TFRC and infection.